|Day Low/High||113.22 / 114.83|
|52 Wk Low/High||84.64 / 132.13|
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
"We're all hurt someplace and we're all looking for a painkiller." -- Katherine, Looking For Mr. Goodbar As I have previously remarked there is an old trading adage that long trading opportunities often occur in stocks that are green in a sea of red...
Eli Lilly's excellent earnings weren't excellent enough.
Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
LLY's stock slide after earnings might present a buying opportunity.
A bunch of pot stocks are in play on Tuesday -- for a reason.
The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.
It shouldn't hurt that the drugmaker beat third-quarter estimates and raised its profit guidance for all of 2018.
Insiders buy for only one reason -- to make money.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
LLY has made a good run this year and now looks like it will correct a bit.
There is clear divergence between the best and the worst performers in each sector this earnings season.
There are concerns that interest rates may start to impact new car sales.
With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.
This is a market driven by macro matters and is not as favorable to stock pickers right now.
The stock still needs to do more work to be convincing.
Straying from these names could land you in quicksand as the 4th quarter begins.
Traders are likely remembering what Facebook stock did when Mark Zuckerberg testified before Congress.
The limited technical data for the recent Eli Lilly spinoff indicate buyers came in early and appear to be holding.
The weekly breakout is pretty impressive on the charts, so let's take a look.
The humanization of pets theme is driving outstanding earnings and share price growth for these 4 names.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Here are some options strategies for this FANG name into tomorrow's report.
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.